Experimental and investigational drugs for the treatment of acute otitis media

References

• Rovers MM, Schilder AG, Zielhuis GA, et al. Otitis media. Lancet. 2004;363:465–473.
   PubMed Web of Science ®Google Scholar
• Leung AKC, Wong AHC. Acute otitis media in children. Recent Pat Inflamm Allergy Drug Discov. 2017;11:32–40.
   PubMed Web of Science ®Google Scholar
• Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep. 2012;12:551–558.
   PubMed Web of Science ®Google Scholar
• Ngo CC, Massa HM, Thornton RB, et al. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS One. 2016;11:e0150949.
   PubMed Web of Science ®Google Scholar
• Bluestone CD. Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J. 2000;19:S37–46.
   PubMed Web of Science ®Google Scholar
• Ovnat Tamir S, Shemesh S, Oron Y, et al. Acute otitis media guidelines in selected developed and developing countries: uniformity and diversity. Arch Dis Child. 2017;102:450–457.
   PubMed Web of Science ®Google Scholar
• Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131:e964–999.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Herva E, Savolainen H, et al. Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis. 2004;38:234–242.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Reed MD. Variations in amoxicillin pharmacokinetic/pharmacodynamic parameters may explain treatment failures in acute otitis media. Paediatr Drugs. 2009;11:243–249.
   PubMedGoogle Scholar
• Tähtinen PA, Laine MK, Huovinen P, et al. A placebo-controlled trial of antimicrobial treatment for acute otitis media. N Engl J Med. 2011;364:116–126.
   PubMed Web of Science ®Google Scholar
• Johnson CE, Belman S. The role of antibacterial therapy of acute otitis media in promoting drug resistance. Paediatr Drugs. 2001;3:639–647.
   PubMedGoogle Scholar
• Thompson PL, Gilbert RE, Long PF, et al. Has UK guidance affected general practitioner antibiotic prescribing for otitis media in children? J Public Health (Oxf). 2008;30:479–486.
   PubMed Web of Science ®Google Scholar
• Marchisio P, Tagliabue M, Klersy C, et al. Patterns in acute otitis media drug prescriptions: a survey of Italian pediatricians and otolaryngologists. Expert Rev Anti Infect Ther. 2014;12:1159–1163.
   PubMed Web of Science ®Google Scholar
• Haggard M. Poor adherence to antibiotic prescribing guidelines in acute otitis media–obstacles, implications, and possible solutions. Eur J Pediatr. 2011;170:323–332.
   PubMed Web of Science ®Google Scholar
• Venekamp RP, Prasad V, Hay AD. Are topical antibiotics an alternative to oral antibiotics for children with acute otitis media and ear discharge? BMJ. 2016;352:i308.
   PubMed Web of Science ®Google Scholar
• Al-Mahallawi AM, Khowessah OM, Shoukri RA. Enhanced non invasive trans -tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: fabrication, in-vitro characterization, and comparative ex-vivo permeation studies. Int J Pharm. 2017;522:157–164.
   PubMed Web of Science ®Google Scholar
• Abdelbary AA, Abd-Elsalam WH, Al-Mahallawi AM. Fabrication of levofloxacin polyethylene glycol decorated nanoliposomes for enhanced management of acute otitis media: statistical optimization, trans-tympanic permeation and in vivo evaluation. Int J Pharm. 2019 Mar 25;559:201–209.
   PubMed Web of Science ®Google Scholar
• Mittal R, Parrish JM, Soni M, et al. Microbial otitis media: recent advancements in treatment, current challenges and opportunities. J Med Microbiol. 2018;67:1417–1425.
   PubMed Web of Science ®Google Scholar
• Kurabi A, Pak KK, Bernhardt M, et al. Discovery of a biological mechanism of active transport through the tympanic membrane to the middle ear. Sci Rep. 2016;6:22663.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Wallin M, Lin Y, et al. Phage therapy for respiratory infections. Adv Drug Deliv Rev. 2018;133:76–86.
   PubMed Web of Science ®Google Scholar
• El-Shibiny A, El-Sahhar S. Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria. Can J Microbiol. 2017;63:865–879.
   PubMed Web of Science ®Google Scholar
• Kurabi A, Schaerer D, Chang L, et al. Optimisation of peptides that actively cross the tympanic membrane by random amino acid extension: a phage display study. J Drug Target. 2018;26:127–134.
   PubMed Web of Science ®Google Scholar
• Bakaletz LO. Bacterial biofilms in the upper airway—evidence for role in pathology and implications for treatment of otitis media. Paediatr Respir Rev. 2012;13:154–159.
   PubMed Web of Science ®Google Scholar
• Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8:623–633.
   PubMed Web of Science ®Google Scholar
• Cope EK, Goldstein-Daruech N, Kofonow JM, et al. Regulation of virulence gene expression resulting from Streptococcus pneumoniae and nontypeable Haemophilus influenzae interactions in chronic disease. PLoS One. 2011;6:e28523.
   PubMed Web of Science ®Google Scholar
• Haggard M. Otitis media: prospects for prevention. Vaccine. 2008;26((Suppl. 7)):G20–G24.
   PubMed Web of Science ®Google Scholar
• Jurcisek JA, Bookwalter JE, Baker BD, et al. The PilA protein of non-typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract. Mol Microbiol. 2007;65:1288–1299.
   PubMed Web of Science ®Google Scholar
• Mokrzan EM, Ward MO, Bakaletz LO. Type IV pilus expression is upregulated in nontypeable Haemophilus influenzae biofilms formed at the temperature of the human nasopharynx. J Bacteriol. 2016;198:2619–2630.
   PubMed Web of Science ®Google Scholar
• Novotny LA, Jurcisek JA, Jr WMO, et al. Antibodies against the majority subunit of type IV pili disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media. Mol Microbiol. 2015;96:276–292.
   PubMed Web of Science ®Google Scholar
• Novotny LA, Clements JD, Goodman SD, et al. Transcutaneous immunization with a band-aid prevents experimental otitis media in a polymicrobial model. Clin Vaccine Immunol. 2017;24:e00563–16.
   PubMed Web of Science ®Google Scholar
• Mokrzan EM, Novotny LA, Brockman KL, et al. Antibodies against the majority subunit (PilA) of the type IV pilus of nontypeable Haemophilus influenzae disperse Moraxella catarrhalis from a dual-species biofilm. MBio. 2018;9:e02423–18.
   PubMed Web of Science ®Google Scholar
• Lappan R, Imbrogno K, Sikazwe C, et al. A microbiome case-control study of recurrent acute otitis media identified potentially protective bacterial genera. BMC Microbiol. 2018;18:13.
   PubMed Web of Science ®Google Scholar
• Cárdenas N, Martín V, Arroyo R, et al. Prevention of recurrent acute otitis media in children through the use of lactobacillus salivarius PS7, a target-specific probiotic strain. Nutrients. 2019;11:E376.
   PubMed Web of Science ®Google Scholar
• Marchisio P, Nazzari E, Torretta S, et al. Medical prevention of recurrent acute otitis media: an updated overview. Expert Rev Anti Infect Ther. 2014;12:611–620.
   PubMed Web of Science ®Google Scholar
• Cohen R, Martin E, de La Rocque F, et al. Probiotics and prebiotics in preventing episodes of acute otitis media in high-risk children: a randomized, double-blind, placebo-controlled study. Pediatr Infect Dis J. 2013;32:810–814.
   PubMed Web of Science ®Google Scholar
• Roos K, Holm SE, Grahn-Håkansson E, et al. Recolonization with selected alpha-streptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis–a randomized placebo-controlled multicentre study. Scand J Infect Dis. 1996;28:459–462.
   PubMedGoogle Scholar
• Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–997.
   PubMedGoogle Scholar
• Di Pierro F, Colombo M, Giuliani MG, et al. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016;20:4601–4606.
   PubMed Web of Science ®Google Scholar
• Di Pierro F, Risso P, Poggi E, et al. Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatr. 2018;70:240–245.
   PubMed Web of Science ®Google Scholar
• Roos K, Håkansson EG, Holm S. Effect of recolonisation with “interfering” alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ. 2001;322:210–212.
   PubMed Web of Science ®Google Scholar
• Tano K, Grahn Håkansson E, Holm SE, et al. A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. Int J Pediatr Otorhinolaryngol. 2002;62:17–23.
   PubMed Web of Science ®Google Scholar
• Santagati M, Scillato M, Patanè F, et al. Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol. 2012;65:23–31.
   PubMedGoogle Scholar
• Marchisio P, Santagati M, Scillato M, et al. Streptococcus salivarius 24SMB administered by nasal spray for the prevention of acute otitis media in otitis-prone children. Eur J Clin Microbiol Infect Dis. 2015;34:2377–2383.
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14:167–182.
   PubMed Web of Science ®Google Scholar
• Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17:295–300.
   PubMed Web of Science ®Google Scholar
• Norhayati MN, Ho JJ, Azman MY. Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database Syst Rev. 2017 Oct 17;10: CD010089. .
   PubMed Web of Science ®Google Scholar
• Vemula SV, Sayedahmed EE, Sambhara S, et al. Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017;16:1141–1154.
   PubMed Web of Science ®Google Scholar
• Villafana T, Falloon J, Griffin MP, et al. Passive and active immunization against respiratory syncytial virus for the young and old. Expert Rev Vaccines. 2017;16:1–13.
   PubMed Web of Science ®Google Scholar
• Glanville N, Johnston SL. Challenges in developing a cross-serotype rhinovirus vaccine. Curr Opin Virol. 2015;11:83–88.
   PubMed Web of Science ®Google Scholar
• Fougeroux C, Holst PJ. Future prospects for the development of cost-effective adenovirus vaccines. Int J Mol Sci. 2017;18:E686.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.
   PubMed Web of Science ®Google Scholar
• Scott P, Rutjes AWS, Bermetz L, et al. Pneumococcal conjugate vaccines: a systematic review of data from randomized controlled trials and observational studies of childhood schedules using 7-, 9-, 10- and 13-valent vaccines; [cited 2019 Apr 25]. Available from: https://www.who.int/immunization/sage/4_PCV_Systematic_Review_nov11.pdf
   Google Scholar
• Esposito S, Principi N. Safety and tolerability of pneumococcal vaccines in children. Expert Opin Drug Saf. 2016;15:777–785.
   PubMed Web of Science ®Google Scholar
• Vojtek I, Nordgren M, Hoet B. Impact of pneumococcal conjugate vaccines on otitis media: A review of measurement and interpretation challenges. Int J Pediatr Otorhinolaryngol. 2017;100:174–182.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Near- elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59::1724–1732.
   PubMed Web of Science ®Google Scholar
• Pichichero M, Kaur R, Scott DA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2:561–568.
   PubMedGoogle Scholar
• Quirk SJ, Haraldsson G, Erlendsdóttir H, et al. Effect of vaccination on pneumococci isolated from the nasopharynx of healthy children and the middle ear of children with otitis media in Iceland. J Clin Microbiol. 2018;56:e01046–18.
   PubMed Web of Science ®Google Scholar
• Morales M, Ludwig G, Ercibengoa M, et al. Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain. PLoS One. 2018;13:e0209048.
   PubMed Web of Science ®Google Scholar
• Allemann A, Frey PM, Brugger SD, et al. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland. Vaccine. 2017;35:1946–1953.
   PubMed Web of Science ®Google Scholar
• Halgrimson WR, Chan KH, Abzug MJ, et al. Incidence of acute mastoiditis in Colorado children in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J. 2014;33:453–457.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Center KJ, Barson WJ, et al. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2015;60:1339–1345.
   PubMed Web of Science ®Google Scholar
• Marchisio P, Esposito S, Picca M, et al. Serotypes not Included in 13-valent pneumococcal vaccine as causes of acute otitis media with spontaneous tympanic membrane perforation in a geographic area with high vaccination coverage. Pediatr Infect Dis J. 2017;36:521–523.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Bottomley MJ, D’Oro U, et al. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp Med. 2016;213::469–481.
   PubMed Web of Science ®Google Scholar
• Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine. 2011;29:8870–8876.
   PubMed Web of Science ®Google Scholar
• Pichichero ME Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vaccines. 2017;16::1181–1190.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36:6883–6891.
   PubMed Web of Science ®Google Scholar
• Feavers I, Knezevic I, Powell M, et al. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada. Vaccine. 2009;27:3681–3688.
   PubMed Web of Science ®Google Scholar
• Pfizer. Pfizer announces serotypes included in 20-valent pneumococcal conjugate vaccine candidate being investigated for the prevention of invasive disease and pneumonia in adults aged 18 years and older; [Cited 2019 Apr 25]. Available from: https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Announces-Serotypes-Included-in-20-Valent-Pneumococcal-Conjugate-Vaccine-Candidate-Being-Investigated-for-the-Prevention-of-Invasive-Disease-and-Pneumonia-in-Adults-Aged-18-Years-and-Older/default.aspx
   Google Scholar
• Kim BG, Kang IJ. Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM, and TEM. Ultramicroscopy. 2008;108:1168–1173.
   PubMed Web of Science ®Google Scholar
• Xu JH, Dai WJ, Chen B, et al. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae. Scand J Immunol. 2015;81:177–185.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 years. Expert Opin Biol Ther. 2018;18:7–17.
   PubMed Web of Science ®Google Scholar
• Balasundaram N, Phan D, Mazzoni D, et al. Acute otitis media in children presenting to the emergency department: is it diagnosed and managed appropriately? J Paediatr Child Health. 2019 Feb 20. DOI:10.1111/jpc.14414.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Antimicrobial stewardship in paediatrics. BMC Infect Dis. 2016;16:424.
   PubMed Web of Science ®Google Scholar
• Paul CR, Gjerde CL, McIntosh G, et al. Teaching the pediatric ear exam and diagnosis of acute otitis media: a teaching and assessment model in three groups. BMC Med Educ. 2017;17:146.
   PubMed Web of Science ®Google Scholar
• Paul CR, Keeley MG, Rebella GS, et al. Teaching pediatric otoscopy skills to pediatric and emergency medicine residents: a cross-institutional study. Acad Pediatr. 2018;18:692–697.
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchisio P, Orenti A, et al. Genetic polymorphisms of functional candidate genes and recurrent acute otitis media with or without tympanic membrane perforation. Medicine (Baltimore). 2015;94:e1860.
   PubMed Web of Science ®Google Scholar
• Principi N, Marchisio P, Rosazza C, et al. Acute otitis media with spontaneous tympanic membrane perforation. Eur J Clin Microbiol Infect Dis. 2017;36:11–18.
   PubMed Web of Science ®Google Scholar